ProPhase Labs to Host Third Quarter 2021 Financial Results Conference Call on Friday, November 12, 2021 at 11:00 a.m. Eastern Time
November 05 2021 - 8:30AM
ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and
genomics company, will hold a conference call on Friday, November
12, 2021 at 11:00 a.m. Eastern time to discuss its results for the
third quarter ended September 30, 2021. A press release detailing
these results will be issued prior to the call.
ProPhase Labs’ CEO and Chairman of the Board of
Directors, Ted Karkus, will host the conference call, followed by a
question-and-answer period.
To access the call, please use the following information:
Date: |
Friday, November 12, 2021 |
Time: |
11:00 a.m. Eastern time, 8:00 a.m. Pacific time |
|
|
Participants can register for the conference
call by navigating to:
https://dpregister.com/sreg/10161532/ef2e0ef568
Please note that registered participants will
receive their dial in number upon registration. Pre-registration
required fields of information include: name, phone, company,
email.
Those without internet access or unable to
pre-register may dial in to the conference call by calling:
Toll free dial in
number: |
1-866-777-2509 |
International
dial in number: |
1-412-317-5413 |
|
|
Please call the conference telephone number 5-10
minutes prior to the start time. Please ask to be joined into the
ProPhase Labs, Inc. conference call. An operator will register your
name, phone and organization.
The conference call will be broadcast live and
available for replay at
https://services.choruscall.com/mediaframe/webcast.html?webcastid=ddkWfCfc
and via the investor relations section of the Company's website
at www.ProPhaseLabs.com.
A replay of the conference call will be
available two hours from when the call ends.
Toll-free replay
number: |
1-877-344-7529 |
International
replay number: |
1-412-317-0088 |
Replay Access
Code: |
10161532 |
|
|
About ProPhase Labs
ProPhase Labs (Nasdaq: PRPH) (“ProPhase”) is a
diversified biotech and genomics company that seeks to leverage its
CLIA lab services to provide whole genome sequencing and research
direct to consumers and build a genomics data base to be used for
further research. The Company continues to provide traditional CLIA
molecular laboratory services, including COVID-19 testing. ProPhase
Precision Medicine, Inc. focuses on genomics testing technologies,
a comprehensive method for analyzing entire genomes, including the
genes and chromosomes in DNA. The data obtained from genomic
testing can help to identify inherited disorders and tendencies,
help predict disease risk, help identify expected drug response,
and characterize genetic mutations, including those that drive
cancer progression.
ProPhase Diagnostics offers a broad array of
clinical diagnostic and testing services at its CLIA certified
laboratories. ProPhase Diagnostics serves patients who may have
SARS-CoV-2 (COVID-19) through both saliva and nasal swab methods.
Critical to COVID testing, results are provided in under 24 hours.
ProPhase Diagnostics also offers PCR (polymerase chain reaction)
testing for Influenzas A and B and RSV; as well as antigen and
antibody/immunity tests to broaden its COVID-19 testing beyond
RT-PCR testing.
ProPhase Global Healthcare, Inc. was formed to
seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into
other countries and to pursue additional healthcare-related
initiatives.
ProPhase Labs has decades of experience
researching, developing, manufacturing, distributing, marketing,
and selling OTC consumer healthcare products and dietary
supplements, including dietary supplements under the TK
Supplements® brand. ProPhase actively pursues strategic
investments and acquisition opportunities for other companies,
technologies, and products. For more information,
visit www.ProPhaseLabs.com.
Investor Contact: CORE IRJules
Abraham917-885-7378julesa@coreir.com
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Apr 2023 to Apr 2024